Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia
Introduction People who are immunocompromised have a poor biological response to vaccinations. This study aims to determine in patients with chronic lymphocytic leukaemia (CLL) if a 3-week pause in Bruton tyrosine kinase inhibitor therapy (BTKi) starting 1 week before delivery of SARS-CoV-2 vaccine...
Saved in:
Main Authors: | Abhishek Abhishek, Jonathan A Cook, Helen M Parry, Anne Francis, Lelia Duley, Vicki S Barber, Paul Moss, Nicholas Peckham |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-09-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/9/e077946.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Role of Bruton's Tyrosine Kinase in B Cell Development
by: Alex Maas, et al.
Published: (2001-01-01) -
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
by: Benjamin M. Heyman, et al.
Published: (2025-02-01) -
Retraction: Bruton’s tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice
by: Frontiers Editorial Office
Published: (2025-01-01) -
A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)
by: Sze-Ting Bong, et al.
Published: (2019-05-01) -
Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
by: Maroun Bou Zerdan, et al.
Published: (2022-01-01)